


A European Sixth Framework Integrated Project



*Translational and Functional Onco-Genomics:
from cancer-oriented genomic screenings to new
diagnostic tools and improved cancer treatment.*


The TRANSFOG Plan for High-Throughput Functional Analysis of Cancer Progression




Participants

Partner	Organisation Name (short name)	Scientific Team Leader
P1 (Admin. Coordinator)	Organization of European Cancer Institutes (OECI)	Guy Storme
P2 (Scient. Coordinator)	Institute for Cancer Research and Treatment (IRCC)	Enzo Medico, Paolo Comoglio
P3	Spanish National Cancer Institute (CNIO)	Mariano Barbacid
P4	German Cancer Research Center (DKFZ)	Annemarie Poustka
P5	Netherlands Cancer Institute (NKI)	Rene Bernards
P6	University Medical Center Utrecht (UMCU)	Johannes L. Bos
P7	FIRC Institute of Molecular Oncology (IFOM)	Marco Pierotti
P8	European Molecular Biology Laboratory (EBI)	Rolf Apweiler
P9	Biomed. Sciences Research Centre “Alexander Fleming” (Fleming)	George Panayotou
P10	Friedrich Miescher Institute for Biomedical Research (FMI)	Nancy Hynes
P11	Agendia BV (Agendia)	Bernhard Sixt
P12	University of Innsbruck Institute of Pathophysiology (IPP)	Stephan Geley
P13	Karolinska Institute (KI)	Edvard Smith
P14	Ludwig Institute for Cancer Research - UCL Branch (LICR-UCL)	Anne Ridley
P15	Ludwig Institute for Cancer Research –Uppsala Branch (LICR-UPP)	Carl-Henrik Heldin
P16	National Interuniversity Consortium Laboratory (LNCIB)	Claudio Schneider
P17	Max-Delbrueck-Center for Molecular Medicine (MDC)	Walter Birchmeier
P18	The Weizmann Institute of Science (WIS)	Yosef Yarden

The TRANSFOG Plan for High-Throughput Functional Analysis of Cancer Progression



TRANSFOG Management



TRANSFOG Management

www.altaweb.eu



The banner features the ALTA logo in large, 3D-style red letters at the top left. To the right of the logo are three red icons: a globe, a padlock, and a camera. Below the logo and icons is a horizontal red line. Underneath this line is a black and white photograph of a man with a beard, wearing a white shirt and tie, sitting at a desk with a computer monitor and a laptop. The laptop screen shows a document with the text 'In vitro microbiology'. To the left of the photograph, the words 'MANAGEMENT', 'MEETINGS', and 'TRAININGS' are listed vertically in white capital letters.

ALTA

MANAGEMENT
MEETINGS
TRAININGS

FLUINNATE

EURORISE

EXERA

EIMID

REBAVAC

MISSION

 ALTA is a service-provider company specialized in managing research projects in the field of biomedicine and biotechnology. Funded in 1998 ALTA has been involved in several projects during the 5th EU Framework Programme and it is directly involved in EU funded projects as partner for management activities in the 6th EU Framework Programme. In addition ALTA is managing several national and international research projects. ALTA people will support you from the idea to the realization of the project proposal helping in finding the proper strategy, forming the European Consortium, putting your science in the most appropriate administrative and management framework.

Project Phases

- Phase I (2005): Initial set-up of experimental procedures for systematic cancer gene functional analysis and clinical validation; establishment of standards and tools for data sharing and mining.
- Phase II (2006-2007): Systematic gene functional analysis and diagnostic validation of new cancer molecular signatures.
- Phase III (2008): collection of results, dissemination of technologies and deliverables to the European cancer research community and cancer hospitals. Exploitation of the achieved results, mainly as new cancer diagnosis tools and screening targets for new cancer drug discovery.

Cell-based screenings

Partner	Screening model
IRCC	Microarray analysis of genes regulated by HGF, EGF and semaphorins in normal and neoplastic, human and mouse cells.
UMCU	Microarray analysis of tumour cell lines after stimulation or inhibition of the Ras, the Akt/PKB and Wnt pathway.
LICR-UCL	Proteomic analysis of ErbB-2-dependent changes in protein expression in immortalized human mammary luminal epithelial cells (HuMLECs)
LICR-UPP	Microarray analysis (Affy chips) of PDGF- or TGFbeta-stimulated normal and cancer cells.
LNCIB	Microarray analysis of tumour cell lines after stimulation or inhibition of the p53 and beta-catenin pathways.
WIS	Gene expression profiling of Erb-B negative feedback loops driven by Erb-B negative regulators in human cancer cell lines.

Target gene functional analysis in cell-based systems

Partner	Functional assay
IRCC	Scattering, angiogenesis, morphogenesis, transformation and invasion of cultured epithelial and endothelial cells.
CNIO	Epigenetic functions (DNA methylation levels).
NKI	Escape from senescence.
UMCU	Reporter gene expression responsive to the Ras, PKB/Akt and Wnt pathways.
FMI	Mammary tissue function: proliferation, migration, and differentiation.
IPP	Apoptosis assays in neoplastic cells
KI	Growth and apoptosis in neoplastic cell lines
LICR-UCL	Cell migration, cell-cell adhesion and transmigration of cancer cells across endothelial cells.
LICR-UPP	PDGF and TGF-beta signaling in cell growth, chemotaxis, actin reorganization, and invasiveness.
LNCIB	Apoptosis, proliferation, cell cycle, morphology, motility, adhesion.
WIS	Negative regulation of ErbB RTK signaling, proliferation and survival; modulation of ErbB2 stability.


Target gene validation in in vivo systems

Partner	Experimental model
CNIO	Creation of genetically modified mice (transgenic, knock-out, knock-in)
FMI	Mouse mammary gland reconstitution
LICR-UCL	Parameters of cancer progression in Drosophila cells
MDC	Assays in lower organism systems (Drosophila and zebrafish)
LICR-UPP	PDGFR-based tumor model in mice


Tumour-based screenings

Partner	Screening model
CNIO	Microarray, CGH and epigenetic analysis focussed on metastatic progression of breast, lung and colon cancer.
IFOM	Microarray analysis in breast and lung cancer, in particular to identify those NO tumours that have a higher risk of metastasising.
Agendia	Gene expression profiling of colon cancer using 25,000 human oligonucleotide microarrays.
LNCIB	cDNA microarray analysis of colon cancer samples, with a specific focus on signaling pathways (FGF and TGF β , invasive ovarian cancer) and hereditary background
MDC	Affychips on colon cancer: a) metastatic and non-metastatic primary tumours, b) metastatic primary tumours and their metastases, and c) metastases to different target organs.


Data Standardization and Integration




Transfog Annotation Layers



OECI members can play a role in TRANSFOG



A proposed frame for interaction



TRANSFOG Workshop: Validation of the Diagnostic Potential of Cancer Genomic Signatures

June 17, 2007 Danish Cancer Society Room 4.1 - Strandboulevarden 49

Agenda

09:00 Get together and welcome by Marco Pierotti and Enzo Medico

09:15 Peter Riegman (Erasmus-MC, Rotterdam): Possible interactions between TRANSFOG and TuBaFrost

09:35 Enzo Medico (IRCC, Candiolo): From cell-based models to clinically relevant gene expression signatures

10:10 Marco Pierotti (IFOM, Milano): Validation of prognostic and predictive signatures in breast cancer

10:50 Ryan Van Laar (Agendia, Amsterdam): Whole genome expression profiling of CRC and development of a clinically useful prognostic test

11:30 Coffee Break

11:45 Josef Jarden (Weizmann, Tel Aviv): Negative feedback regulators of growth factor signaling affecting breast cancer metastasis.

12:25 Miguel Angel Piris (CNIO, Madrid): Definition and validation of molecular cancer signatures at CNIO

www.transfog.org



TRANSFOG

TRANSslational and Functional Onco-Genomics



Home

- [About the project](#)
- [Consortium](#)
- [Public Documents](#)
- [News and events](#)
- [Publications](#)

Home

Welcome to the TRANSFOG website

The TRANSFOG project aims at the systematic identification and functional characterization of novel cancer genes with high potential diagnostic and therapeutic value in breast, colon and lung cancer. The TRANSFOG Partners will bring together world recognised competences and resources to reach the following, integrated research objectives



June 2007						
<						>
Sun	Mon	Tue	Wed	Thu	Fri	Sat
27	28	29	30	31	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
1	2	3	4	5	6	7

Event:
WP4-5 workshop

Location & date:
INNSBRUCK, 14-17/03/2007

Thank You!



www.transfog.org